Jefferies on BridgeBio Pharma (BBIO): expecting Attruby sales to beat consensus estimates

April 15, 2026 5:10 PM

Jefferies analyst Andrew Tsai reiterated a Buy rating and $100.00 price target on BridgeBio Pharma (NASDAQ: BBIO)The analyst commented, "For ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found